Evidence map›Paper›PMID 38396957›Full record

ArticleInternational journal of molecular sciences2024

Identification of Hit Compounds Using Artificial Intelligence for the Management of Allergic Diseases.

Junhyoung Byun, Junhu Tai, Byoungjae Kim, Jaehyeong Kim, Semyung Jung, Juhyun Lee, Youn Woo Song, Jaemin Shin, Tae Hoon Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 3 countries.

Junhyoung ByunDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.ORCID 0009-0007-3462-8233
Junhu TaiDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.ORCID 0000-0003-1491-9889
Byoungjae KimDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.ORCID 0000-0002-7186-4290
Jaehyeong KimDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.
Semyung JungDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.
Juhyun LeeDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.
Youn Woo SongDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.
Jaemin ShinDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.ORCID 0000-0002-2090-9612
Tae Hoon KimDepartment of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 02842 Seoul, Republic of Korea.
Korea University · KR

Funding

Institute for Information & communication Technology Planning & evaluation IITP-2023-2020-0-01819Korea Health Industry Development Institute HI17C0387Korea University no grant numberKorea University Medical Center no grant numberKorea University Medical Center Anam Hospital no grant numberMinistry of Health and Welfare HR22C1302Ministry of Science and ICT 2020R1C1C1012288National Research Foundation of Korea 2017R1A2B2003575National Research Foundation of Korea NRF-2020R1A2C1006398
6 · The paper itself

Abstract

This study aimed to identify and evaluate drug candidates targeting the kinase inhibitory region of suppressor of cytokine signaling (SOCS) 3 for the treatment of allergic rhinitis (AR). Utilizing an artificial intelligence (AI)-based new drug development platform, virtual screening was conducted to identify compounds inhibiting the SH2 domain binding of SOCS3. Luminescence assays assessed the ability of these compounds to restore JAK-2 activity diminished by SOCS3. Jurkat T and BEAS-2B cells were utilized to investigate changes in SOCS3 and STAT3 expression, along with STAT3 phosphorylation in response to the identified compounds. In an OVA-induced allergic rhinitis mouse model, we measured serum levels of total IgE and OVA-specific IgE, performed real-time PCR on nasal mucosa samples to quantify Th2 cytokines and IFN-γ expression, and conducted immunohistochemistry to analyze eosinophil levels. Screening identified 20 hit compounds with robust binding affinities. As the concentration of SOCS3 increased, a corresponding decrease in JAK2 activity was observed. Compounds

Indexed as

Artificial IntelligenceRhinitis, AllergicAnimalsCytokinesDisease Models, AnimalImmunoglobulin EMiceMice, Inbred BALB CNasal MucosaOvalbuminSuppressor of Cytokine Signaling ProteinsCytokinesImmunoglobulin EOvalbuminSuppressor of Cytokine Signaling Proteinsallergic rhinitisartificial intelligencenew drug development platformSOCS3

Identifiers

PMID38396957
PMCPMC10889320
OpenAlexW4391811499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.